Immunotherapy in indolent Non-Hodgkin's Lymphoma
Authors:
Open Access
- 18 May 2022
- journal article
- research article
- Published by Elsevier in Leukemia Research Reports
- Vol. 17, 100325
Abstract
No abstract availableKeywords
This publication has 78 references indexed in Scilit:
- Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator RituximabBioDrugs, 2013
- Novel CD20 monoclonal antibodies for lymphoma therapyJournal of Hematology & Oncology, 2012
- Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphomaBlood, 2011
- New Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoid MalignanciesBioDrugs, 2011
- Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemiaBlood, 2009
- Primary Treatment of Waldenström Macroglobulinemia With Dexamethasone, Rituximab, and CyclophosphamideJournal of Clinical Oncology, 2007
- Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, EpratuzumabClinical Cancer Research, 2005
- Phase I/II Study of Galiximab, an Anti-CD80 Antibody, for Relapsed or Refractory Follicular LymphomaJournal of Clinical Oncology, 2005
- Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2005
- Therapeutic monoclonal antibodies in oncologyJournal of the Royal Society of Medicine, 2005